EUCTR2005-002711-25-SK进行中（未招募）1 期
Dose finding study of trazodone in the treatment of patients with primary insomnia
ACRAF S.p.A.0 个研究点目标入组 160 人开始时间: 2006年3月30日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients may be enrolled under the following circumstances:
- •·male or female patients with no limitation of race, aged between 18 and 65 years (limits included);
- •·clinical diagnosis of either primary insomnia or insomnia associated with mild non-psychotic psychiatric disorders (DSM-IV code 300.9) based on subjective reporting of current history of insomnia, as defined by DSM-IV (code 307.42), presenting in the last month, at least two of the following characteristics:
- •·predominant complaint of difficulty of initiating or maintaining sleep, or non restorative sleep;
- •·sleep disturbance (or associated daytime fatigue) causing clinically significant distress or impairment in social, occupational, or other important areas of functioning;
- •·frequent (3 or more per night) nocturnal awakenings with difficulty returning to sleep;
- •·Time to Sleep Onset (TSO) > 30 min in at least three nights of the week preceding the enrolment (Visit 2);
- •·Total Sleep Time (TST) of 4-6 hours in at least three nights of the week preceding the enrolment (Visit 2);
- •·Zung Anxiety Scale score < 40
- •·Zung Depression Scale score < 40
- •·normal physical, neurological, and laboratory profile with no acute, chronic, or recurrent conditions that might affect the study;
- •·discontinuation of benzodiazepines or other over-the-counter sleep medication or other psychotropic drugs for 1-2 weeks, depending upon duration of action;
- •·consent to maintain a regular work and activity schedule, avoid naps, consume no alcohol, and have no caffeine after 15:00 hours;
- •·signed and dated informed consent form.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients cannot enter the trial under the following circumstances:
- •·history of occurrence of adverse reactions or known hypersensitivity to the experimental drugs and their eccipients;
- •·history or presence of clinically significant hepatic or renal disease or other medical disease that might compromise the study;
- •·serious respiratory insufficiency, myastenia gravis, narrow angle glaucoma;
- •·myocardial infarction within 6 months prior to start of the treatment;
- •·sleep disturbance occurring exclusively during the course of narcolepsy, breathing-related sleep disorders, circadian sleep disorder, or a parasomnia;
- •·sleep disturbance occurring exclusively during the course of another mental disorder (i.e, major depressive disorder, generalized anxiety disorder, a delirium);
- •·sleep disturbances due to the direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a general medical conditions;
- •·recent history of alcoholism;
- •·regular use of any medication that in the Investigators’ opinion would interfere with the study;
- •·thyroid dysfunction, even if pharmacologically corrected;
- •·clinically significant abnormalities on the pre-study physical examination, vital signs, ECG and laboratory tests;
- •·positive urine drug screen for CNS-active drugs (cocaine, amphetamines, cannabinoids, oppioids);
- •·concomitant diseases that might cause insomnia (i.e., pain sindromes, cardiovascular or gastrointestinal or muscle-skeletal disorders, and urological patologies characterized by nicturia);
- •·pregnancy, lactation, or female of childbearing age with a positive urine pregnancy test result during the screening assessment. Women of childbearing age must use a medically acceptable form of contraception during the entire study period;
- •·participation to another trial involving any investigational drug during the past 60 days.
- •The absence of any of the above mentioned inclusion criteria or presence of any of the above mentioned exclusion criteria during the course of the study will result in the withdrawal of the patient.
研究者
相似试验
进行中（未招募）
不适用
Dose finding study of trazodone in the treatment of patients with primary insomniaPrimary Insomnia (or insomnia associated with mild non-psychotic psychiatric disorders)EUCTR2005-002711-25-CZACRAF S.p.A.160
进行中（未招募）
不适用
DOSE-FINDING STUDY OF TRAZODONE IN THE TREATMENT OF PATIENTS WITH PRIMARY INSOMNIATREATMENT OF THE INSOMNIAMedDRA version: 6.1Level: PTClassification code 10022437EUCTR2005-002711-25-ITANGELINI160
进行中（未招募）
1 期
A study of the effectiveness and safety of low doses od trazodone in patients affected by painful diabetic neuropathy: randomized, controlled, pilot study.Painful diabetic neuropathyMedDRA version: 19.0Level: LLTClassification code 10012683Term: Diabetic peripheral neuropathySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 19.0Level: PTClassification code 10012680Term: Diabetic neuropathySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 19.0Level: SOCClassification code 10014698Term: Endocrine disordersSystem Organ Class: 10014698 - Endocrine disordersEUCTR2016-002772-27-HUA.C.R.A.F. SpA (Angelini SpA)120
进行中（未招募）
1 期
A study of the effectiveness and safety of low doses od trazodone in patients affected by painful diabetic neuropathy: randomized, controlled, pilot study.Painful diabetic neuropathyMedDRA version: 20.0Level: LLTClassification code 10012683Term: Diabetic peripheral neuropathySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10012680Term: Diabetic neuropathySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: SOCClassification code 10014698Term: Endocrine disordersSystem Organ Class: 10014698 - Endocrine disordersEUCTR2016-002772-27-CZAngelini S.p.A.120
进行中（未招募）
1 期
A study of the effectiveness and safety of low doses od trazodone in patients affected by painful diabetic neuropathy: randomized, controlled, pilot study.Painful diabetic neuropathyMedDRA version: 20.0Level: LLTClassification code 10012683Term: Diabetic peripheral neuropathySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10012680Term: Diabetic neuropathySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: SOCClassification code 10014698Term: Endocrine disordersSystem Organ Class: 10014698 - Endocrine disordersEUCTR2016-002772-27-PLA.C.R.A.F. SpA (Angelini SpA)120